Νέα

Αυτός το πεδίο είναι κενό.

Κατευθυντήριες οδηγίες απο το Βρετανικό National Institute of Clinical Excelence (NICE)

Guidance

 

NICE has developed medical technology guidance on the transurethral resection in saline (TURis) system.

NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

NICE has said that the TURis system can be used instead of a surgical system called ‘monopolar transurethral resection of the prostate’ (or monopolar TURP).

Healthcare teams may want to use the TURis system instead of monopolar TURP because:

  • there is no risk of a rare complication called transurethral resection syndrome and
  • it is less likely that a blood transfusion after surgery will be needed.

Compared with monopolar TURP, the TURis system can save money depending on the equipment a hospital currently uses.

Using the TURis system may shorten the time spent in hospital after prostate surgery. It may also reduce the chances of the man having to go into hospital again because of complications from the surgery. The savings are greater if these factors are taken into account.

 

 
  •  

 

 

Korean J Urol. 2011 Nov; 52(11): 763–768.
Published online 2011 Nov 17. doi:  10.4111/kju.2011.52.11.763
PMCID: PMC3242990

Comparative Analysis of the Efficacy and Safety of Conventional Transurethral Resection of the Prostate, Transurethral Resection of the Prostate in Saline (TURIS), and TURIS-Plasma Vaporization for the Treatment of Benign Prostatic Hyperplasia: A Pilot Study

 

Yong Taec Lee, Young Woo Ryu, Dong Min Lee, Sang Wook Park, Seung Hee Yum, and June Hyun Han

CONCLUSIONS

In this pilot study, we confirmed that TURIS and TURIS-V were effective surgical treatments for BPH in addition to conventional TUR-P, and TURIS-V was not inferior to conventional TUR-P and TURIS for safety. TURIS-V represents a promising endoscopic treatment alternative for patients with BPH, showing good efficacy, reduced morbidity, fast recovery, and satisfactory follow-up. Our results suggest that further studies with a prospective randomized design and a long-term follow-up are warranted.